drugset / Trial / NCT00038519

Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor

NCT00038519

Phase 2/3 Completed 16 enrolled Abbott
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to study the safety and efficacy of Amprenavir/ritonavir or saquinavir/ritonavir in HIV infected patients that have failed Kaletra as their second protease inhibitor based HAART.

Timeline

Start
2001-04
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Amprenavir Other / unclassified
Subject Saquinavir Small molecule
Background Ritonavir Other / unclassified